← Leaderboards
Donald H Burke
Indiana University Bloomington
$7,145,522
Attributed
$7,426,939
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,426,939 · 8
By mechanism
R01$6,174,032 · 3
R21$1,251,045 · 3
P41$1,862 · 2
Top collaborators
- Margaret J Lange2 shared
- Stefan G Sarafianos2 shared
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusBaseViralGeneticCellsRna-Directed Dna PolymeraseAptamerAntiviral AgentsMolecularHiv-1ElementsStructureIn VitroMutationVariantAmino Acid SequenceResistanceModificationComplexFutureGene TherapyNucleic AcidsPharmaceutical PreparationsMaps
Grant awards (27)
Mechanism of Microbial DNA Hypervariation through Mutagenic Transposition$288,600
R01 · FY2021 · GM · contact PI
Mechanism of Microbial DNA Hypervariation through Mutagenic Transposition$92,072
R01 · FY2021 · GM · contact PI
Mechanism of Microbial DNA Hypervariation through Mutagenic Transposition$288,714
R01 · FY2020 · GM · contact PI
Mechanism of Microbial DNA Hypervariation through Mutagenic Transposition$288,825
R01 · FY2019 · GM · contact PI
Gene Therapy for HIV Using Aptamers that Target Reverse Transcriptase$579,079
R01 · FY2017 · AI · contact PI
Strain-specific and pan-filoviral aptamer recognition of Ebola virus glycoproteins$239,754
R21 · FY2017 · AI · contact PI
RNA Aptamers that Differentiate Among HIV-1 Capsid Assembly States$230,250
R21 · FY2017 · AI
Gene Therapy for HIV Using Aptamers that Target Reverse Transcriptase$579,079
R01 · FY2016 · AI · contact PI
RNA Aptamers that Differentiate Among HIV-1 Capsid Assembly States$191,875
R21 · FY2016 · AI
Strain-specific and pan-filoviral aptamer recognition of Ebola virus glycoproteins$187,630
R21 · FY2016 · AI · contact PI
Gene Therapy for HIV Using Aptamers that Target Reverse Transcriptase$579,079
R01 · FY2015 · AI · contact PI
Gene Therapy for HIV Using Aptamers that Target Reverse Transcriptase$569,073
R01 · FY2014 · AI · contact PI
Determinates of anti-HIV nucleic acid aptamer potency and resistance$431,199
R01 · FY2012 · AI · contact PI
Determinates of anti-HIV nucleic acid aptamer potency and resistance$432,990
R01 · FY2011 · AI · contact PI
Determinates of anti-HIV nucleic acid aptamer potency and resistance$434,575
R01 · FY2010 · AI · contact PI
EVALUATION OF CANDIDATE VACCINE TECHNOLOGIES USING AGENT BASED COMPUTATIONAL ME$1,091
P41 · FY2010 · RR · contact PI
Determinates of anti-HIV nucleic acid aptamer potency and resistance$413,773
R01 · FY2009 · AI · contact PI
Determinates of anti-HIV nucleic acid aptamer potency and resistance$60,777
R01 · FY2009 · AI · contact PI
Determinates of anti-HIV nucleic acid aptamer potency and resistance$57,122
R01 · FY2009 · AI · contact PI
Determinates of anti-HIV nucleic acid aptamer potency and resistance$39,261
R01 · FY2009 · AI · contact PI
EVALUATION OF CANDIDATE VACCINE TECHNOLOGIES USING AGENT BASED COMPUTATIONAL ME$771
P41 · FY2009 · RR · contact PI
Determinates of anti-HIV nucleic acid aptamer potency and resistance$370,646
R01 · FY2008 · AI · contact PI
RNA aptamers to inhibit natural and evolved RT variants$215,318
R21 · FY2006 · AI · contact PI
RNA aptamers to inhibit natural and evolved RT variants$186,218
R21 · FY2005 · AI
RNA-PROTEIN INTERACTIONS$229,759
R01 · FY2002 · AI
RNA-PROTEIN INTERACTIONS$222,991
R01 · FY2001 · AI
RNA-PROTEIN INTERACTIONS$216,418
R01 · FY2000 · AI